Clinical Trial Update: Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) clinical trial investigating intracoronary nicardipine to prevent coronary microvascular dysfunction after PCI was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Microvascular Dysfunction

Drugs mentioned

• Nicardipine (nicardipine)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Coronary Artery Disease | EARLY_Phase 1 | Status: WITHDRAWN